SELLAS Life Sciences Group, Inc.
SLS
$1.82
-$0.09-4.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.04% | -20.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.36% | -24.38% | |||
| Operating Income | -13.36% | 24.38% | |||
| Income Before Tax | -13.56% | 13.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.56% | 13.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.56% | 13.72% | |||
| EBIT | -13.36% | 24.38% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -1.21% | 27.33% | |||
| Normalized Basic EPS | -1.21% | 37.46% | |||
| EPS Diluted | -5.74% | 27.33% | |||
| Normalized Diluted EPS | -1.21% | 37.46% | |||
| Average Basic Shares Outstanding | 12.30% | 18.61% | |||
| Average Diluted Shares Outstanding | 12.30% | 18.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||